1. Neves J, Leitz D, Kraut S, Brandenberger C, Agrawal R, Weissmann N, Muhlfeld C, Mall MA, Altamura S, Muckenthaler MU: Disruption of the hepcidin/ferroportin regulatory system causes pulmonary iron overload and restrictive lung disease. EBioMedicine 2017, 20:230-239
2.Mleczko-Sanecka K, da Silva AR, Call D, Neves J, Schmeer N, Damm G, Seehofer D, Muckenthaler MU: Imatinib and spironolactone suppress hepcidin expression. Haematologica 2017;102:1173-1184
3. Muckenthaler MU, Rivella S, Hentze MW, Galy B: A red carpet for iron metabolism. Cell 2017, 168:344-361
4. Vinchi F, Costa da Silva M, Ingoglia G, Petrillo S, Brinkman N, Zuercher A, Cerwenka A, Tolosano E, Muckenthaler MU: Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease. Blood. 2016, 28;127(4):473-86.
5. Guida C, Altamura S, Klein FA, Galy B, Boutros M, Ulmer AJ, Hentze MW, Muckenthaler MU: A novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia. Blood 2015; 125(14):2265-75
6.ltamura S, Kessler R, Gröne HJ, Gretz N, Hentze MW, Galy B, Muckenthaler MU: Resistance of Ferroportin to Hepcidin Binding causes Exocrine Pancreatic Failure and Fatal Iron Overload. Cell Metab. 2014; 20(2):359-67